Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 13
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
BIBW 2992 (TOVOK) and BSC Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.23
NCT00656136
2.
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-Negative Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.10
Eudract 2006-002018-36, NCT00425854
3.
Phase II Trial of BIBW 2992 in Patients With HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.11
EUDRACT 2007-004805-80, NCT00431067
4.
BIBW 2992 in Head&Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.28
67,969 IND, NCT00514943
5.
Phase II Single Arm BIBW 2992 in NSCLC With EGFR Activating Mutations
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.22
NCT00525148
6.
A Multi-Centre 3-Arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-Resistant Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1239.3
NCT00706628
7.
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.5
EUDRACT2006-002814-37, NCT00708214
8.
Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
20 and over
Pharmaceutical / Industry
1200.33
NCT00711594
9.
BIBW 2992 With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
1200.36
NCT00727506
10.
Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
Pharmaceutical / Industry
1200.26
NCT00748709
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute